Advertisement

Impact of body mass index on outcomes in an Asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors

Published:August 05, 2022DOI:https://doi.org/10.1016/j.clgc.2022.08.001

      Abstract

      Objectives

      : To clarify the impact of body mass index (BMI) on treatment outcomes including survival, tumor response, and adverse events (AEs) in patients with advanced renal cell carcinoma (RCC) or urothelial carcinoma (UC) treated with immune checkpoint inhibitors (ICIs) in an Asian population.

      Methods

      : We retrospectively evaluated 309 patients with advanced RCC or UC who received ICIs between September 2016 and July 2021. The patients were divided into high- (i.e., ≥25 kg/m2) and low-BMI (<25 kg/m2) groups according to the BMI at the time of treatment initiation.

      Results

      : Overall, 57 patients (18.4%) were classified into the high-BMI group. In RCC patients treated with ICIs as first-line therapy or UC treated with pembrolizumab, progression-free survival (PFS) (hazard ratio [HR]: 1.39, p=0.309; HR: 1.06, p=0.842), overall survival (OS) (HR: 0.78, p=0.701; HR: 0.99, p=0.983), and objective response rate (ORR) (p=0.163; p=0.553) were comparable between the high- and low-BMI groups. In RCC patients treated with nivolumab monotherapy as later-line therapy, OS (HR: 0.37, p=0.101) and ORR (p=0.102) were comparable, but PFS was significantly longer in the high-BMI group (HR: 0.39, p=0.0272). Further, multivariate analysis showed that BMI was not an independent factor of PFS or OS in all the treatment groups (any, p>0.05). As for AE profiles, in nivolumab monotherapy, the rate was significantly higher in the high-BMI group (p=0.0203), whereas in the other two treatments, the rate was comparable.

      Conclusions

      : BMI was not associated with survival or response rates of advanced RCC or UC patients treated with ICIs in an Asian population. AEs might frequently develop in high-BMI patients with RCC in nivolumab monotherapy.

      MicroAbstract

      : We aimed to clarify the impact of body mass index in patients with advanced renal cell carcinoma (RCC) and urothelial carcinoma (UC), treated with immune checkpoint inhibitors in an Asian population. There was no direct association between obesity (i.e., body mass index ≥25 kg/m2) and treatment outcomes in this population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Xu W
        • Atkins MB
        • McDermott DF
        Checkpoint inhibitor immunotherapy in kidney cancer.
        Nat Rev Urol. 2020; 17 (PMID): 137-150https://doi.org/10.1038/s41585-020-0282-3
        • Powles T
        Recent eupdate to the esmo clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2021; 32 (PMID): 422-423https://doi.org/10.1016/j.annonc.2020.11.016
        • Cathomas R
        • Lorch A
        • Bruins HM
        • Compérat EM
        • Cowan NC
        • Efstathiou JA
        • Fietkau R
        • Gakis G
        • Hernández V
        • Espinós EL
        • Neuzillet Y
        • Ribal MJ
        • Rouanne M
        • Thalmann GN
        • van der Heijden AG
        • Veskimäe E
        • Alfred Witjes J
        • Milowsky MI
        The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma.
        Eur Urol. 2022; 81 (PMID): 95-103https://doi.org/10.1016/j.eururo.2021.09.026
        • Motzer RJ
        • Tannir NM
        • McDermott DF
        • Aren Frontera O
        • Melichar B
        • Choueiri TK
        • Plimack ER
        • Barthelemy P
        • Porta C
        • George S
        • Powles T
        • Donskov F
        • Neiman V
        • Kollmannsberger CK
        • Salman P
        • Gurney H
        • Hawkins R
        • Ravaud A
        • Grimm MO
        • Bracarda S
        • Barrios CH
        • Tomita Y
        • Castellano D
        • Rini BI
        • Chen AC
        • Mekan S
        • McHenry MB
        • Wind-Rotolo M
        • Doan J
        • Sharma P
        • Hammers HJ
        • Escudier B
        Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
        N Engl J Med. 2018; 378 (PMID: PMC5972549): 1277-1290https://doi.org/10.1056/NEJMoa1712126
        • Fradet Y
        • Bellmunt J
        • Vaughn DJ
        • Lee JL
        • Fong L
        • Vogelzang NJ
        • Climent MA
        • Petrylak DP
        • Choueiri TK
        • Necchi A
        • Gerritsen W
        • Gurney H
        • Quinn DI
        • Culine S
        • Sternberg CN
        • Nam K
        • Frenkl TL
        • Perini RF
        • de Wit R
        • Bajorin DF
        Randomized phase iii keynote-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up.
        Ann Oncol. 2019; 30 (PMID: PMC6594457): 970-976https://doi.org/10.1093/annonc/mdz127
        • Cortellini A
        • Bersanelli M
        • Santini D
        • Buti S
        • Tiseo M
        • Cannita K
        • Perrone F
        • Giusti R
        • De Tursi M
        • Zoratto F
        • Marconcini R
        • Russano M
        • Zeppola T
        • Anesi C
        • Filetti M
        • Marchetti P
        • Botticelli A
        • Gelibter A
        • De Galitiis F
        • Vitale MG
        • Rastelli F
        • Tudini M
        • Silva RR
        • Atzori F
        • Chiari R
        • Ricciuti B
        • De Giglio A
        • Migliorino MR
        • Mallardo D
        • Vanella V
        • Mosillo C
        • Bracarda S
        • Rinaldi S
        • Berardi R
        • Natoli C
        • Ficorella C
        • Porzio G
        • Ascierto PA
        Another side of the association between body mass index (bmi) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (pd-1)/programmed cell death-ligand 1 (pd-l1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
        Eur J Cancer. 2020; 128 (PMID): 17-26https://doi.org/10.1016/j.ejca.2019.12.031
        • Guzman-Prado Y
        • Ben Shimol J
        • Samson O
        Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: A systematic review and meta-analysis.
        Cancer Immunol Immunother. 2021; 70 (PMID): 89-100https://doi.org/10.1007/s00262-020-02663-z
        • Nie RC
        • Chen GM
        • Wang Y
        • Yuan SQ
        • Zhou J
        • Duan JL
        • Liu WW
        • Chen S
        • Cai MY
        • Li YF
        Association between body mass index and survival outcomes in patients treated with immune checkpoint inhibitors: Meta-analyses of individual patient data.
        J Immunother. 2021; 44 (PMID: PMC8500279): 371-375https://doi.org/10.1097/cji.0000000000000389
        • Rogado J
        • Romero-Laorden N
        • Sanchez-Torres JM
        • Ramos-Levi AM
        • Pacheco-Barcia V
        • Ballesteros AI
        • Arranz R
        • Lorenzo A
        • Gullon P
        • Garrido A
        • Serra López-Matencio JM
        • Donnay O
        • Adrados M
        • Costas P
        • Aspa J
        • Alfranca A
        • Mondejar R
        • Colomer R
        Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-pd-1 antibodies.
        Oncoimmunology. 2020; 9 (PMID: PMC7185216)1751548https://doi.org/10.1080/2162402x.2020.1751548
        • Cortellini A
        • Bersanelli M
        • Buti S
        • Cannita K
        • Santini D
        • Perrone F
        • Giusti R
        • Tiseo M
        • Michiara M
        • Di Marino P
        • Tinari N
        • De Tursi M
        • Zoratto F
        • Veltri E
        • Marconcini R
        • Malorgio F
        • Russano M
        • Anesi C
        • Zeppola T
        • Filetti M
        • Marchetti P
        • Botticelli A
        • Antonini Cappellini GC
        • De Galitiis F
        • Vitale MG
        • Rastelli F
        • Pergolesi F
        • Berardi R
        • Rinaldi S
        • Tudini M
        • Silva RR
        • Pireddu A
        • Atzori F
        • Chiari R
        • Ricciuti B
        • De Giglio A
        • Iacono D
        • Gelibter A
        • Occhipinti MA
        • Parisi A
        • Porzio G
        • Fargnoli MC
        • Ascierto PA
        • Ficorella C
        • Natoli C
        A multicenter study of body mass index in cancer patients treated with anti-pd-1/pd-l1 immune checkpoint inhibitors: When overweight becomes favorable.
        J Immunother Cancer. 2019; 7 (PMID: PMC6391761): 57https://doi.org/10.1186/s40425-019-0527-y
        • Di Filippo Y
        • Dalle S
        • Mortier L
        • Dereure O
        • Dalac S
        • Dutriaux C
        • Leccia MT
        • Legoupil D
        • Saiag P
        • Brunet-Possenti F
        • Arnnault JP
        • Maubec E
        • Granel-Brocard F
        • De Quatrebarbes J
        • Aubin F
        • Lesimple T
        • Beylot-Barry M
        • Stoebner PE
        • Dupuy A
        • Stephan A
        • Grob JJ
        • Lefevre W
        • Oriano B
        • Allayous C
        • Lebbé C
        • Montaudié H
        Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: Analysis of the melbase french cohort data.
        Ann Oncol. 2021; 32 (PMID): 542-551https://doi.org/10.1016/j.annonc.2020.12.012
        • Kichenadasse G
        • Miners JO
        • Mangoni AA
        • Rowland A
        • Hopkins AM
        • Sorich MJ
        Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.
        JAMA Oncol. 2020; 6 (PMID: PMC6990855): 512-518https://doi.org/10.1001/jamaoncol.2019.5241
        • Boi SK
        • Orlandella RM
        • Gibson JT
        • Turbitt WJ
        • Wald G
        • Thomas L
        • Buchta Rosean C
        • Norris KE
        • Bing M
        • Bertrand L
        • Gross BP
        • Makkouk A
        • Starenki D
        • Farag KI
        • Sorge RE
        • Brown JA
        • Gordetsky J
        • Yasin H
        • Garje R
        • Nandagopal L
        • Weiner GJ
        • Lubaroff DM
        • Arend RC
        • Li P
        • Zakharia Y
        • Yang E
        • Salem AK
        • Nepple K
        • Marquez-Lago TT
        • Norian LA
        Obesity diminishes response to pd-1-based immunotherapies in renal cancer.
        J Immunother Cancer. 2020; 8 (PMID: PMC7757487)https://doi.org/10.1136/jitc-2020-000725
        • De Giorgi U
        • Procopio G
        • Giannarelli D
        • Sabbatini R
        • Bearz A
        • Buti S
        • Basso U
        • Mitterer M
        • Ortega C
        • Bidoli P
        • Ferraù F
        • Crinò L
        • Frassoldati A
        • Marchetti P
        • Mini E
        • Scoppola A
        • Verusio C
        • Fornarini G
        • Cartenì G
        • Caserta C
        • Sternberg CN
        Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab.
        Clin Cancer Res. 2019; 25 (PMID): 3839-3846https://doi.org/10.1158/1078-0432.Ccr-18-3661
        • Labadie BW
        • Liu P
        • Bao R
        • Crist M
        • Fernandes R
        • Ferreira L
        • Graupner S
        • Poklepovic AS
        • Duran I
        • Maleki Vareki S
        • Balar AV
        • Luke JJ
        Bmi, irae, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
        J Transl Med. 2019; 17 (PMID: PMC6878694): 386https://doi.org/10.1186/s12967-019-02144-7
        • De Filippi R
        • Morabito F
        • Santoro A
        • Tripepi G
        • D'Alò F
        • Rigacci L
        • Ricci F
        • Morelli E
        • Zinzani PL
        • Pinto A
        Body mass index is not associated with survival outcomes and immune-related adverse events in patients with hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
        J Transl Med. 2021; 19 (PMID: PMC8638339): 489https://doi.org/10.1186/s12967-021-03134-4
        • Gülave B
        • Hew MN
        • de Groot JS
        • Rodwell L
        • Teerenstra S
        • Fabriek BO
        High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with pd-(l)1 inhibitors across different solid tumors.
        ESMO Open. 2021; 6 (PMID: PMC8086026)100107https://doi.org/10.1016/j.esmoop.2021.100107
        • Motzer RJ
        • Escudier B
        • McDermott DF
        • George S
        • Hammers HJ
        • Srinivas S
        • Tykodi SS
        • Sosman JA
        • Procopio G
        • Plimack ER
        • Castellano D
        • Choueiri TK
        • Gurney H
        • Donskov F
        • Bono P
        • Wagstaff J
        • Gauler TC
        • Ueda T
        • Tomita Y
        • Schutz FA
        • Kollmannsberger C
        • Larkin J
        • Ravaud A
        • Simon JS
        • Xu LA
        • Waxman IM
        • Sharma P
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373 (PMID): 1803-1813https://doi.org/10.1056/NEJMoa1510665
        • Rini BI
        • Plimack ER
        • Stus V
        • Gafanov R
        • Hawkins R
        • Nosov D
        • Pouliot F
        • Alekseev B
        • Soulieres D
        • Melichar B
        • Vynnychenko I
        • Kryzhanivska A
        • Bondarenko I
        • Azevedo SJ
        • Borchiellini D
        • Szczylik C
        • Markus M
        • McDermott RS
        • Bedke J
        • Tartas S
        • Chang YH
        • Tamada S
        • Shou Q
        • Perini RF
        • Chen M
        • Atkins MB
        • Powles T
        Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380 (PMID): 1116-1127https://doi.org/10.1056/NEJMoa1816714
        • Motzer RJ
        • Penkov K
        • Haanen J
        • Rini B
        • Albiges L
        • Campbell MT
        • Venugopal B
        • Kollmannsberger C
        • Negrier S
        • Uemura M
        • Lee JL
        • Vasiliev A
        • Miller Jr., WH
        • Gurney H
        • Schmidinger M
        • Larkin J
        • Atkins MB
        • Bedke J
        • Alekseev B
        • Wang J
        • Mariani M
        • Robbins PB
        • Chudnovsky A
        • Fowst C
        • Hariharan S
        • Huang B
        • di Pietro A
        • Choueiri TK
        Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380 (PMID): 1103-1115https://doi.org/10.1056/NEJMoa1816047
        • Bellmunt J
        • de Wit R
        • Vaughn DJ
        • Fradet Y
        • Lee JL
        • Fong L
        • Vogelzang NJ
        • Climent MA
        • Petrylak DP
        • Choueiri TK
        • Necchi A
        • Gerritsen W
        • Gurney H
        • Quinn DI
        • Culine S
        • Sternberg CN
        • Mai Y
        • Poehlein CH
        • Perini RF
        • Bajorin DF
        Pembrolizumab as second-line therapy for advanced urothelial carcinoma.
        N Engl J Med. 2017; 376 (PMID: PMC5635424): 1015-1026https://doi.org/10.1056/NEJMoa1613683
        • Eisenhauer EA
        • Therasse P
        • Bogaerts J
        • Schwartz LH
        • Sargent D
        • Ford R
        • Dancey J
        • Arbuck S
        • Gwyther S
        • Mooney M
        • Rubinstein L
        • Shankar L
        • Dodd L
        • Kaplan R
        • Lacombe D
        • Verweij J
        New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1).
        Eur J Cancer. 2009; 45 (PMID): 228-247https://doi.org/10.1016/j.ejca.2008.10.026
      1. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf )?. 2022

        • Leiter A
        • Doucette J
        • Krege S
        • Lin CC
        • Hahn N
        • Ecke T
        • Sonpavde G
        • Bamias A
        • Oh WK
        • Galsky MD
        Obesity and outcomes in patients with metastatic urothelial carcinoma.
        Bladder Cancer. 2016; 2 (PMID: PMC4969712): 341-349https://doi.org/10.3233/blc-160047
        • Martin L
        • Birdsell L
        • Macdonald N
        • Reiman T
        • Clandinin MT
        • McCargar LJ
        • Murphy R
        • Ghosh S
        • Sawyer MB
        • Baracos VE
        Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.
        J Clin Oncol. 2013; 31 (PMID): 1539-1547https://doi.org/10.1200/jco.2012.45.2722
        • Ishihara H
        • Kondo T
        • Omae K
        • Takagi T
        • Iizuka J
        • Kobayashi H
        • Tanabe K
        Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment.
        Target Oncol. 2016; 11 (PMID): 605-617https://doi.org/10.1007/s11523-016-0430-0
        • James BR
        • Tomanek-Chalkley A
        • Askeland EJ
        • Kucaba T
        • Griffith TS
        • Norian LA
        Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth.
        J Immunol. 2012; 189 (PMID: PMC3401274): 1311-1321https://doi.org/10.4049/jimmunol.1100587
        • Hale M
        • Itani F
        • Buchta CM
        • Wald G
        • Bing M
        • Norian LA
        Obesity triggers enhanced mdsc accumulation in murine renal tumors via elevated local production of ccl2.
        PLoS One. 2015; 10 (PMID: PMC4358922)e0118784https://doi.org/10.1371/journal.pone.0118784
        • Incio J
        • Ligibel JA
        • McManus DT
        • Suboj P
        • Jung K
        • Kawaguchi K
        • Pinter M
        • Babykutty S
        • Chin SM
        • Vardam TD
        • Huang Y
        • Rahbari NN
        • Roberge S
        • Wang D
        • Gomes-Santos IL
        • Puchner SB
        • Schlett CL
        • Hoffmman U
        • Ancukiewicz M
        • Tolaney SM
        • Krop IE
        • Duda DG
        • Boucher Y
        • Fukumura D
        • Jain RK
        Obesity promotes resistance to anti-vegf therapy in breast cancer by up-regulating il-6 and potentially fgf-2.
        Sci Transl Med. 2018; 10 (PMID: PMC5936748)https://doi.org/10.1126/scitranslmed.aag0945
        • Wang Z
        • Aguilar EG
        • Luna JI
        • Dunai C
        • Khuat LT
        • Le CT
        • Mirsoian A
        • Minnar CM
        • Stoffel KM
        • Sturgill IR
        • Grossenbacher SK
        • Withers SS
        • Rebhun RB
        • Hartigan-O'Connor DJ
        • Méndez-Lagares G
        • Tarantal AF
        • Isseroff RR
        • Griffith TS
        • Schalper KA
        • Merleev A
        • Saha A
        • Maverakis E
        • Kelly K
        • Aljumaily R
        • Ibrahimi S
        • Mukherjee S
        • Machiorlatti M
        • Vesely SK
        • Longo DL
        • Blazar BR
        • Canter RJ
        • Murphy WJ
        • Monjazeb AM
        Paradoxical effects of obesity on t cell function during tumor progression and pd-1 checkpoint blockade.
        Nat Med. 2019; 25 (PMID: PMC6324991): 141-151https://doi.org/10.1038/s41591-018-0221-5
        • Bennett DA
        How can i deal with missing data in my study?.
        Aust N Z J Public Health. 2001; 25 (PMID, DOI): 464-469